Tocilizumab for the treatment of severe coronavirus disease 2019

Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory‐confirmed severe COVID‐19 who received tocilizumab and co...

Full description

Saved in:
Bibliographic Details
Published in:J Med Virol
Main Authors: Alattar, Rand, Ibrahim, Tawheeda B. H., Shaar, Shahd H., Abdalla, Shiema, Shukri, Kinda, Daghfal, Joanne N., Khatib, Mohamed Y., Aboukamar, Mohamed, Abukhattab, Mohamed, Alsoub, Hussam A., Almaslamani, Muna A., Omrani, Ali S.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7267594/
https://ncbi.nlm.nih.gov/pubmed/32369191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25964
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items